EMA Authorised: Emblaveo (avibactam;aztreonam) — Pfizer Europe MA EEIG

View source ↗

Summary

The EMA authorised Emblaveo (avibactam/aztreonam) for treating certain Gram-negative bacterial infections, including urinary tract infections, healthcare-associ…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Healthcare-associated Pneumonia
• Soft Tissue Infections
• Urinary Tract Infection

Drugs mentioned

• EMBLAVEO (AZTREONAM AND AVIBACTAM)

Snippet

Status: Authorised. Therapeutic area: Gram-Negative Bacterial Infections;Urinary Tract Infections;Healthcare-Associated Pneumonia;Soft Tissue Infections. MAH: Pfizer Europe MA EEIG. Decision date: 20/02/2026